Amedisys (NASDAQ:AMED) Sees Strong Trading Volume – Here’s What Happened

Amedisys, Inc. (NASDAQ:AMEDGet Free Report) saw strong trading volume on Tuesday . 500,604 shares traded hands during mid-day trading, an increase of 45% from the previous session’s volume of 346,021 shares.The stock last traded at $91.40 and had previously closed at $92.68.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Cantor Fitzgerald reissued a “neutral” rating and set a $101.00 price objective on shares of Amedisys in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft downgraded shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 target price for the company. in a research note on Monday, July 29th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $100.67.

Read Our Latest Research Report on AMED

Amedisys Trading Down 0.6 %

The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average price is $96.32 and its two-hundred day moving average price is $95.85. The firm has a market cap of $2.96 billion, a PE ratio of 35.91, a P/E/G ratio of 1.87 and a beta of 0.78.

Amedisys (NASDAQ:AMEDGet Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The health services provider reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). The business had revenue of $587.67 million during the quarter, compared to analysts’ expectations of $586.75 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Amedisys’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.98 EPS. As a group, sell-side analysts forecast that Amedisys, Inc. will post 4.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amedisys

Several institutional investors have recently made changes to their positions in the stock. Alpine Associates Management Inc. boosted its holdings in Amedisys by 0.9% during the second quarter. Alpine Associates Management Inc. now owns 1,280,897 shares of the health services provider’s stock worth $117,586,000 after buying an additional 11,000 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Amedisys by 4.0% during the second quarter. Dimensional Fund Advisors LP now owns 514,166 shares of the health services provider’s stock worth $47,202,000 after purchasing an additional 19,660 shares during the last quarter. Calamos Advisors LLC boosted its position in Amedisys by 11.6% during the second quarter. Calamos Advisors LLC now owns 397,347 shares of the health services provider’s stock worth $36,476,000 after purchasing an additional 41,220 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Amedisys by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock valued at $33,400,000 after purchasing an additional 9,004 shares during the last quarter. Finally, Highbridge Capital Management LLC raised its stake in shares of Amedisys by 34.7% during the 2nd quarter. Highbridge Capital Management LLC now owns 323,200 shares of the health services provider’s stock worth $29,670,000 after buying an additional 83,200 shares during the last quarter. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

About Amedisys

(Get Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Read More

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.